Market Overview

UPDATE: Oppenheimer Downgrades Emerson to Perform on Lack of Catalysts to Growth

Related EMR
8 Biggest Price Target Changes For Wednesday
Benzinga's Top Downgrades
My Dividend Growth Portfolio - Q3 2016 Summary (Seeking Alpha)

Oppenheimer reduced its rating on Emerson (NYSE: EMR) from Outperform to Perform and lowered its price target from $57 to $53.

Oppenheimer commented, "We are downgrading shares of EMR to Perform from Outperform, based on lack of high conviction catalysts to drive multiple expansion, and nearterm risk associated with exposure to capital spending. Initial guidance outlook for msd-hsd EPS growth appears a potentially more opportunistic backdrop for expectations, but does include a combined 17c headwind from pension and overlapping stock compensation plans (partially offset by ~6c favorable from lower restructuring spend, and material restructuring benefits)."

Emerson closed at $48.36 on Monday.

Latest Ratings for EMR

Oct 2016UBSDowngradesNeutralSell
Oct 2016HSBCInitiates Coverage on
Oct 2016BerenbergInitiates Coverage onSell

View More Analyst Ratings for EMR
View the Latest Analyst Ratings

Posted-In: OppenheimerAnalyst Color Downgrades Intraday Update Analyst Ratings


Related Articles (EMR)

View Comments and Join the Discussion!